A preliminary study done by New York's Grossman School of Medicine reports on the use of HCQ+AZT+Zinc versus HCQ+AZT alone in four New York Hospitals has issued its report. Here's the key finding of the abstract. Zinc sulfate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU, and mortality or transfer to hospice for patients who were never admitted to the ICU.  After adjusting for the time at which zinc sulfate was added to our protocol, an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09) reduction in mortality or transfer to hospice remained significant (OR 0.449, 95% CI 0.271-0.744).  Conclusion: This study provides the first in vivo evidence that zinc sulfate in combination with hydroxychloroquine may play a role in therapeutic management for COVID-19. The "main finding of this study is that after adjusting for the timing of zinc therapy, we found...(Read Full Post)